tiprankstipranks
Advertisement
Advertisement

COGT Stock Latest News

Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers
Company AnnouncementsCogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers
1d ago
COGT
Cogent Biosciences assumed with a Buy at Jefferies
PremiumThe Fly
Cogent Biosciences assumed with a Buy at Jefferies
12d ago
COGT
Cogent Biosciences: FDA accepts NDA for bzuclastinib in NonAdvSM
PremiumThe Fly
Cogent Biosciences: FDA accepts NDA for bzuclastinib in NonAdvSM
12d ago
COGT
Cogent announces additional results from SUMMIT trial of bezuclastinib
PremiumThe Fly
Cogent announces additional results from SUMMIT trial of bezuclastinib
27d ago
COGT
Cogent Biosciences price target raised to $35 from $34 at Baird
PremiumThe Fly
Cogent Biosciences price target raised to $35 from $34 at Baird
1M ago
COGT
Buy Rating Backed by Bezuclastinib’s Late-Stage Catalysts, Dual-Launch Potential, and Differentiated Profile in GIST and SM
PremiumRatingsBuy Rating Backed by Bezuclastinib’s Late-Stage Catalysts, Dual-Launch Potential, and Differentiated Profile in GIST and SM
1M ago
COGT
Cogent Biosciences price target raised to $52 from $39 at Piper Sandler
Premium
The Fly
Cogent Biosciences price target raised to $52 from $39 at Piper Sandler
1M ago
COGT
Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains
Premium
Company Announcements
Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains
1M ago
COGT
Cogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year
PremiumThe Fly
Cogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year
1M ago
COGT
Cogent Biosciences sees cash runway into 2028
PremiumThe Fly
Cogent Biosciences sees cash runway into 2028
1M ago
COGT
Cogent Biosciences: Breakthrough Bezuclastinib Data, Expanding SM Franchise, and Emerging Pipeline Support Raised $54 Buy Target
PremiumRatings
Cogent Biosciences: Breakthrough Bezuclastinib Data, Expanding SM Franchise, and Emerging Pipeline Support Raised $54 Buy Target
2M ago
COGT
Cogent Biosciences announcse U.S. BTD for bezuclastinib
PremiumThe Fly
Cogent Biosciences announcse U.S. BTD for bezuclastinib
2M ago
COGT
Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial
PremiumCompany AnnouncementsCogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial
2M ago
COGT
Cogent to initiate New Drug Application submission for bezuclastinib
Premium
The Fly
Cogent to initiate New Drug Application submission for bezuclastinib
2M ago
COGT
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Multiple 2026 NDA Filings Underpin Reiterated Buy and $52 Target
Premium
Ratings
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Multiple 2026 NDA Filings Underpin Reiterated Buy and $52 Target
2M ago
COGT
Cogent Biosciences announces anticipated 2026 commercial, clinical milestones
PremiumThe Fly
Cogent Biosciences announces anticipated 2026 commercial, clinical milestones
3M ago
COGT
Aligos Therapeutics initiated with a Buy at UBS
PremiumThe Fly
Aligos Therapeutics initiated with a Buy at UBS
3M ago
IVA
KOD
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Favorable FDA Outlook Underpin Upgraded $52 Buy Rating
PremiumRatings
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Favorable FDA Outlook Underpin Upgraded $52 Buy Rating
3M ago
COGT
Cogent Biosciences price target raised to $52 from $50 at H.C. Wainwright
PremiumThe Fly
Cogent Biosciences price target raised to $52 from $50 at H.C. Wainwright
3M ago
COGT
Cogent Biosciences submits NDA for bezuclastinib in NonAdvSM
PremiumThe FlyCogent Biosciences submits NDA for bezuclastinib in NonAdvSM
3M ago
COGT
Cogent Biosciences price target raised to $67 from $65 at JPMorgan
Premium
The Fly
Cogent Biosciences price target raised to $67 from $65 at JPMorgan
3M ago
COGT
Cogent Biosciences Reports Positive Clinical Trial Results
Premium
Company Announcements
Cogent Biosciences Reports Positive Clinical Trial Results
4M ago
8K
COGT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >